Alnylam Presents New Pre-clinical Data On Subcutaneously Delivered RNAi Therapeutics For Cardiovascular Metabolic Disease At Arteriosclerosis, Thrombosis And Vascular Biology 2014 Scientific Sessions

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data from RNAi therapeutic programs toward genetically validated targets in cardiovascular metabolic diseases, including ALN-PCSsc targeting PCSK9 for the treatment of hypercholesterolemia, and a newly named program, ALN-AC3, targeting apolipoprotein C-III (apoCIII) for the treatment of hypertriglyceridemia. These data are being presented at the Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) 2014 Scientific Sessions being held May 1-3 in Toronto, Ontario. In an oral presentation titled “ A Subcutaneous, Potent and Durable RNAi Platform Targeting Metabolic Diseases, Genes PCSK9, ApoCIII and ANGPLT3” new pre-clinical data utilizing the company’s GalNAc-siRNA conjugate platform demonstrated robust and durable knockdown of these key cardiovascular metabolic disease targets. Amongst other data, Alnylam presented new single-dose durability data for ALN-PCSsc showing robust knockdown of PCSK9 and reductions in LDL-C that support once-monthly and possibly once-quarterly subcutaneous dosing regimens. Specifically, a single dose of ALN-PCSsc maintained greater than 50% LDL-C reductions for over three months in the absence of statin co-administration. The company plans to file an investigational new drug (IND) application, or IND equivalent, for ALN-PCSsc by late 2014 or early 2015.

“As evidenced by these data presented at ATVB, we are building the beginnings of a promising pipeline of RNAi therapeutics toward genetically validated disease targets in the cardio-metabolic space. We see this as an attractive area for continued investment for Alnylam given the large number of liver-expressed disease-causing genes and the emerging profile of our GalNAc-conjugate platform enabling subcutaneous delivery with potent disease gene knockdown, a wide therapeutic index, and highly durable effects. These features are exemplified with ALN-PCSsc, where new non-human primate pre-clinical results demonstrate significant knockdown of PCSK9 and reductions in LDL-C with very durable effects, lasting over three months. We believe that this level of durability should readily support a once-monthly and possibly a once-quarterly subcutaneous dosing regimen, and thus represents what should be a highly competitive profile with anti-PCSK9 monoclonal antibodies. We look forward to advancing ALN-PCSsc toward clinical trials by the end of this year or early next,” said Kevin Fitzgerald, Ph.D., Senior Director, Research at Alnylam. “In addition, new rodent data with ALN-AC3, our GalNAc-siRNA conjugate targeting apoCIII, showed up to 95% knockdown of ApoCIII and up to 68% reduction in triglycerides. These pre-clinical results warrant further efforts to advance this new RNAi therapeutic program into later stages of development.”

If you liked this article you might like

Alnylam Shares Skyrocket on Clinical Study Results - Biotech Movers

Intra-Cellular Leaps; Schizophrenia Drug Shows Less Side Effects-Biotech Movers

Tesla's Rally Has Died: Stock Falls to Sixth Worst Performer in Russell 1000

Biotech Movers: Inovio, Neurocrine, Alnylam

Biotech Movers: Ionis, Alnylam, Amicus, Minerva